# A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

> **NCT05876832** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shijiazhuang Yiling Pharmaceutical Co. Ltd** · enrollment: 312 (estimated)

## Conditions studied

- Acute Myeloid Leukemia With FLT3/ITD Mutation

## Interventions

- **DRUG:** XY0206
- **DRUG:** Salvage Chemotherapy

## Key facts

- **NCT ID:** NCT05876832
- **Lead sponsor:** Shijiazhuang Yiling Pharmaceutical Co. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-06-15
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2023-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05876832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05876832, "A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05876832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*